Skip to main
KAPA

KAPA Stock Forecast & Price Target

KAPA Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kairos Pharma Ltd's clinical-stage developments demonstrate a strong positive outlook, particularly illustrated by the interim Phase 2 results for ENV-105, which show a median progression-free survival of 13.7 months and an 86% clinical benefit rate in advanced prostate cancer patients. The company's robust research and development activity is supported by two Department of Defense grants, which not only bolster its ENV-105 and ENV-205 initiatives but also underscore its commitment to advancing innovative cancer treatments. Additionally, with a solid financial foundation characterized by controlled cash burn and adequate capital to sustain its strategic plans, Kairos Pharma is well-positioned to execute its growth strategies within the oncology sector.

Bears say

Kairos Pharma Ltd. has shown some biological activity in its therapeutics, with seven of nine evaluable patients achieving PSA declines from baseline; however, this has not translated into financial success. The company reported no product revenues for the quarter ended June 30, 2025, indicating challenges in commercializing its therapeutic offerings. Additionally, Kairos Pharma incurred a significant net loss of approximately $1.4 million for the quarter and $2.7 million for the first half of 2025, raising concerns about its financial sustainability and operational viability in the competitive biopharmaceutical market.

KAPA has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kairos Pharma Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kairos Pharma Ltd (KAPA) Forecast

Analysts have given KAPA a Strong Buy based on their latest research and market trends.

According to 3 analysts, KAPA has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kairos Pharma Ltd (KAPA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.